Seeking Alpha

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...
Nasdaq

Kymera Therapeutics Advances Oral Immunology Pipeline with Promising New Program Targeting IRF5 for Autoimmune Diseases

Kymera Therapeutics has announced the launch of a new program targeting the IRF5 transcription factor, enhancing its portfolio of oral immunology treatments for autoimmune and rheumatic diseases. The ...
BioWorld

IRF5 inhibitors show efficacy across autoimmune models

Interferon regulatory factor 5 (IRF5) is a transcription factor activated downstream of Toll-like receptors (TLRs) 7, 8 and 9, and is predominantly expressed in dendritic cells, B cells, monocytes and ...
MarketWatch

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025

The MarketWatch News Department was not involved in the creation of this content. BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and ...
manilatimes

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to ...